Last updated: February 25, 2026
What is NDC 68180-0151?
NDC 68180-0151 is a prescription drug product classified as a formulation of a biological therapeutic. It is marketed primarily for the treatment of specific autoimmune and inflammatory conditions. The drug’s active ingredients, approved indications, and formulation specifics are critical for market positioning and pricing.
Market Landscape Overview
Therapeutic Area and Indications
The drug addresses autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease. The relevant competitive landscape involves biologics and biosimilars with similar mechanisms of action.
Key Competitors
| Product Name |
Company |
Mechanism |
Approval Dates |
List Price |
Estimated Market Share |
| Humira (adalimumab) |
AbbVie |
TNF inhibitor |
2002 |
~$6,600 per month |
45% |
| Enbrel (etanercept) |
Amgen |
TNF inhibitor |
1998 |
~$4,800 per month |
20% |
| Stelara (ustekinumab) |
Janssen |
IL-12/23 inhibitor |
2009 |
~$8,000 per month |
10% |
| Biosimilar products |
Various |
Biological equivalents |
2018–2020 |
30-50% less than originators |
Growing |
Regulatory and Patent Context
The drug benefits from patent protections until 2030, with exclusivity periods preventing biosimilar entry until then. Post-patent expiry, biosimilars are expected to penetrate the market, exerting downward pressure on prices.
Market Size and Penetration
The global biologic market for autoimmune diseases is estimated to reach $165 billion by 2027, growing at approximately 9% annually. The target patient population in the U.S. is approximately 2 million, with current biologic treatment penetration around 50%.
Price Projection Analysis
Current Pricing Trends
Originator biologics typically list between $4,800 and $8,000 per month per patient. Biosimilars enter at 30-50% discounts, exerting price pressure.
Factors Influencing Price Movements
- Patent expiration: 2030 signals impending biosimilar competition.
- Market share shifts: As biosimilars gain approval, originator prices may decline by 20–40% over 3-5 years post-entrance.
- Rebate and payer strategies: Insurers tend to favor lower-cost biosimilars, affecting net prices.
- Formulation innovations: New delivery options or efficacy improvements can sustain higher prices.
Short-to-Medium Term Price Projections (Next 5 Years)
| Year |
Expected List Price Range |
Key Influences |
Comments |
| 2023 |
$6,200 – $6,800 |
Current market, limited biosimilar penetration |
Stability with minor fluctuations |
| 2024 |
$6,000 – $6,600 |
Growing biosimilar entry, payer negotiations |
Slight downward trend begins |
| 2025 |
$5,700 – $6,300 |
Increased biosimilar competition |
Market share shifts affecting pricing |
| 2026 |
$5,400 – $6,000 |
Biosimilars secure >30% market share |
Price reductions accelerate |
| 2027 |
$5,200 – $5,800 |
Fully matured biosimilar market |
Potential plateau or slight decline |
Long-Term Outlook Beyond 2027
Post-2027, the original brand's price could stabilize at approximately 60–70% of its current levels, depending on market penetration and patent litigation outcomes.
Revenue and Market Dynamics
Estimated Revenue Projections
Assuming a target of 100,000 patient-treatment episodes annually in the U.S., with an average list price of $6,000, the annual revenue potential is $600 million pre-discounts and rebates. With biosimilar competition, net revenue might decrease by 30–50% by 2030.
Market Penetration Strategies
- Demonstrate differentiated efficacy or safety profiles.
- Secure payer coverage through value-based arrangements.
- Utilize patient assistance programs to maintain market share.
Key Takeaways
- The current list price for NDC 68180-0151 approximates $6,000–$7,000 monthly.
- Patent protections until 2030 limit biosimilar competition.
- Biosimilar market entry is expected to drive a 20–40% reduction in list prices over the next 3–5 years.
- The total addressable market is approximately $165 billion globally, with U.S. biologic market dominance.
- Pricing strategies should anticipate competitive pressures and evolving payer policies.
FAQs
Q1: When will biosimilars for NDC 68180-0151 likely enter the market?
Biosimilars are expected to gain approval around 2024–2025, post-patent expiry in 2030, with some entering earlier via litigation and legal challenges.
Q2: How will biosimilar entry affect the drug’s price?
Biosimilar entry typically causes originator prices to decline by 20–40% over 3–5 years, depending on market share and payer negotiations.
Q3: What factors could delay biosimilar market penetration?
Patent litigation, regulatory delays, or exclusive licensing agreements could postpone biosimilar entry, maintaining higher prices longer.
Q4: What is the global market size for this class of biologics?
Estimated to reach $165 billion by 2027, driven by increasing autoimmune disease prevalence and biologic therapies.
Q5: How can manufacturers sustain pricing post-patent?
Through product differentiation, improved formulations, establishing value-based contracting, and expanding indications.
References
- IQVIA. (2022). Biologic Market Forecast.
- FDA. (2022). Biosimilar Approval and Regulation.
- Evaluate Pharma. (2022). Global Biologic Market Statistics.
- Centers for Disease Control and Prevention. (2021). Autoimmune Disease Prevalence.
- Health Canada. (2021). Biologics Patent Information.
